Clues to Why a Breakthrough Pancreatic Cancer Drug Eventually Stops Working September 30, 2026 | The New York Times Gina Kolata Researchers are asking why patients, like former Senator Ben Sasse, inevitably develop resistance to the drug daraxonrasib. The work involved an unusual effort by three groups: Break Through Cancer, a nonprofit that brings researchers together to tackle challenging problems in cancer treatment; the Lustgarten Foundation, which supports research on pancreatic cancer; and Revolution Medicines, which makes daraxonrasib. Read the full story on The New York Times...

Continue reading

We can prevent ovarian cancer. Women deserve the option. | Opinion August 13, 2026 | USA Today Dr. Joseph Sakran and Dr. Rebecca Stone Cancer prevention opportunities are rare. When one presents itself safely during an operation a patient is already having, we have a responsibility to consider it. Read the full story on USA Today...

Continue reading

Fallopian tube removal may lower ovarian cancer risk August 10, 2026 | Good Morning America ABC News' Rhiannon Ally and chief medical correspondent Dr. Tara Narula report on a procedure that may reduce ovarian cancer risk by up to 80%. Watch the feature here...

Continue reading

Most ‘Ovarian Cancer’ Isn’t. And That Fact Can Save Lives. The vast majority of cases begin in the fallopian tubes — and removing them can reduce the risk by nearly 80 percent. July 28, 2026 | Gina Kolata   Kira Wynn will do almost anything to avoid ovarian cancer, which killed her mother. “My mom thought she’d pulled a muscle in her side,” Ms. Wynn said. Her mother’s doctor, she added, “told her to do physical therapy.” As is often the case with ovarian cancer, Ms. Wynn’s mother’s disease was already at an advanced stage when she was diagnosed. She......

Continue reading

How scientists found a weakness in one of the deadliest 'undruggable' cancers May 24, 2026 | Calrolyn Johnson “This is the news we've been waiting for. This is the breakthrough — it's been a long time coming,” said Break Through Cancer President Tyler Jacks, PhD, in a recent Washington Post feature examining the decades-long scientific effort that led to KRAS-targeted therapies for pancreatic cancer. In this new article for The Washington Post, Carolyn Johnson traces the scientific journey behind daraxonrasib, from the early discovery of KRAS as a cancer driver to the clinical results that are reshaping expectations for one......

Continue reading